OR WAIT null SECS
Novavax announces the first doses of Nuvaxovid COVID-19 vaccine have begun shipping to European Union member states.
Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced on Feb. 23, 2022 that the first doses of its Nuvaxovid COVID-19 vaccine have begun shipping to European Union (EU) member states. Nuvaxovid is the first protein-based COVID-19 vaccine authorized for use in Europe.
Nuvaxovid doses are shipping from Novavax’ Netherlands distribution center to EU member states. The first wave of shipments includes several countries, such as Germany, France, and Austria, with shipments to additional EU member states to quickly follow.
The European Commission (EC) granted conditional marketing authorization (CMA) for Nuvaxovid to prevent COVID-19 caused by SARS-Cov-2 in individuals 18 years of age or older. The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended authorization of the vaccine in all 27 EU member states in December 2021.
"Today's announcement paves the way for vaccination with Nuvaxovid to begin in Europe within the coming days. The Novavax COVID-19 vaccine provides a differentiated option to bolster vaccination rates across Europe," said Stanley C. Erck, president and CEO of Novavax, in the press release. "Nuvaxovid has demonstrated efficacy, a reassuring safety and tolerability profile, and is built on a well-understood protein-based vaccine platform used for other vaccines for decades."